Komori
Other Disclosures4978ReproCELL IncorporatedMaterials and Chemicals

Notice Concerning the Expansion of the Well-Aging Business and the Launch of Sales of the Well-Aging Supplement “Gurutama Aging”

ReproCELL has launched its Well-Aging Business as a new B2C business, applying knowledge developed in the research and medical fields, and has begun selling its in-house-developed supplement "グルたまエイジング" as its first offering. The company plans to expand the business into testing and health management products.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Well-aging businessWELLMILLGenetic age measurement kitグルたまエイジング (well-aging supplement)
Applicable field (uses covered by this announcement)

Personal health management, B2C healthcare

Launch date29 September 2026 (sales launch, actual)
Impact on Business Performance

The impact on consolidated results for the current fiscal year is currently expected to be immaterial.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Research literature and other sources from Japan and overseas

Announced details
ItemDetails
Names of Products / Services CoveredWell-aging business, WELLMILL, Genetic age measurement kit, グルたまエイジング (well-aging supplement)
Launch date29 September 2026 (sales launch, actual)
Applicable areaPersonal health management, B2C healthcare
Impact on Business PerformanceThe impact on consolidated results for the current fiscal year is currently expected to be immaterial.
SourceResearch literature and other sources from Japan and overseas
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To apply knowledge of iPS cells and reprogramming technologies developed over approximately 20 years to products and services that support everyday health management, with the aim of strengthening its B2C business and creating new customer segments and revenue opportunities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Expansion of the Well-Aging Business and the Launch of Sales of the Well-Aging Supplement “Gurutama Aging” | ReproCELL Incorporated (4978) timely disclosure | Komori